Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Business time plan concept and planning corporate or personal schedule or wasting minutes as a group of timepieces or clocks coming out of a large clock as a 3D illustration.

Opinion

Drug Price Critiques Ignore a Crucial Consideration—Time

Drug pricing criticism often fixates on a price at a single point in time but drug pricing is never static.

October 8, 2025

3 min read

Melanie Whittington

Regulatory

Marks Finds His Next Role as Lilly Snags Another Former FDA Regulator

Six months after his controversial departure from the top spot at the FDA’s biologics division, Peter Marks has landed at Eli Lilly, joining former colleague Rachael Anatol, who was ousted from the agency not long after Marks.

October 7, 2025

1 min read

Heather McKenzie

a hand with a lit match lighting another match

IPOs

UPDATE: MapLight Seeks $227M IPO for Neuropsych Portfolio

MapLight laid out the terms of its planned IPO in a regulatory filing on Monday, providing greater detail about what the funds will be used for.

October 7, 2025

3 min read

Tristan Manalac

Auction concept: Hands holding paddle with numbers

Mergers & acquisitions

Pfizer Beat Out Two Other Metsera Suitors for Takeover

Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New York pharma, however, offered the smoothest transaction with the greatest likelihood of success.

October 7, 2025

3 min read

Tristan Manalac

Obesity

Skye’s CB1 Inhibitor Shows ‘Intriguing Synergy’ With Wegovy, Despite Mid-Stage Obesity Fail

Skye Bioscience’s nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when combined with Wegovy, according to analysts at William Blair.

October 7, 2025

2 min read

Tristan Manalac

Pictured: Amgen's office in Massachusetts/iStock,

Drug pricing

Amgen Hops on DTC Train To Offer Repatha at 60% Discount

Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction from the current wholesale acquisition cost of $527.70.

October 7, 2025

2 min read

Tristan Manalac

Tariffs

Most Life Sciences Companies Not Planning New Investments After Tariffs: Report

A new survey from CRB showed that most manufacturing initiatives in the U.S. made in response to tariffs are coming from Big Pharma companies, while smaller biotechs are left to hope “the situation doesn’t get worse.”

October 7, 2025

3 min read

Dan Samorodnitsky

Business

BioSpace Honors 40 Under 40 Winners Whose Impact Reflects Industry’s Grit

The inaugural 40 Under 40 cohort includes CEOs, leaders who have founded or co-founded their company and executives from a range of disciplines. Winners’ accomplishments include shaping drug development, achieving key FDA milestones and launching a new field of study.

October 7, 2025

2 min read

Angela Gabriel